Diagnosis and Management of Type 2 Diabetic Kidney Disease
Tóm tắt
Type 2 diabetic kidney disease (DKD) is the most common cause of CKD and ESRD worldwide, and carries with it enormous human and societal costs. The goal of this review is to provide an update on the diagnosis and management of DKD based on a comprehensive review of the medical literature. Topics addressed include the evolving presentation of DKD, clinical differentiation of DKD from non-DKD, a state-of-the-art evaluation of current treatment strategies, and promising emerging treatments. It is expected that the review will help clinicians to diagnose and manage patients with DKD.
Từ khóa
Tài liệu tham khảo
Afkarian, 2016, Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014, JAMA, 316, 602, 10.1001/jama.2016.10924
Bailey, 2014, Chronic kidney disease in US adults with type 2 diabetes: An updated national estimate of prevalence based on Kidney Disease: Improving Global Outcomes (KDIGO) staging, BMC Res Notes, 7, 415, 10.1186/1756-0500-7-415
Tuttle, 2014, Diabetic kidney disease: A report from an ADA Consensus Conference, Am J Kidney Dis, 64, 510, 10.1053/j.ajkd.2014.08.001
Bakris, 2014, Microalbuminuria as a risk predictor in diabetes: The continuing saga, Diabetes Care, 37, 867, 10.2337/dc13-1870
Adler, 2003, Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64), Kidney Int, 63, 225, 10.1046/j.1523-1755.2003.00712.x
Dwyer, 2012, Renal dysfunction in the presence of normoalbuminuria in type 2 diabetes: Results from the DEMAND study, Cardiorenal Med, 2, 1, 10.1159/000333249
Kramer, 2003, Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus, JAMA, 289, 3273, 10.1001/jama.289.24.3273
Penno, 2011, Clinical significance of nonalbuminuric renal impairment in type 2 diabetes, J Hypertens, 29, 1802, 10.1097/HJH.0b013e3283495cd6
Thomas, 2009, Nonalbuminuric renal impairment in type 2 diabetic patients and in the general population (national evaluation of the frequency of renal impairment cO-existing with NIDDM [NEFRON] 11), Diabetes Care, 32, 1497, 10.2337/dc08-2186
Chang, 2011, Renal outcomes in patients with type 2 diabetes with or without coexisting non-diabetic renal disease, Diabetes Res Clin Pract, 92, 198, 10.1016/j.diabres.2011.01.017
Pham, 2007, Prevalence of nondiabetic renal disease in diabetic patients, Am J Nephrol, 27, 322, 10.1159/000102598
Tone, 2005, Clinical features of non-diabetic renal diseases in patients with type 2 diabetes, Diabetes Res Clin Pract, 69, 237, 10.1016/j.diabres.2005.02.009
Sharma, 2013, The modern spectrum of renal biopsy findings in patients with diabetes, Clin J Am Soc Nephrol, 8, 1718, 10.2215/CJN.02510213
2007, KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease, Am J Kidney Dis, 49, S12
2016, Standards of medical care in diabetes-2016: Summary of revisions, Diabetes Care, 39, S4
1998, Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38, BMJ, 317, 703, 10.1136/bmj.317.7160.703
Ismail-Beigi, 2012, Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients, Kidney Int, 81, 586, 10.1038/ki.2011.415
Berl, 2005, Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial, J Am Soc Nephrol, 16, 2170, 10.1681/ASN.2004090763
Ruggenenti, 2004, Preventing microalbuminuria in type 2 diabetes, N Engl J Med, 351, 1941, 10.1056/NEJMoa042167
Parving, 2001, The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes, N Engl J Med, 345, 870, 10.1056/NEJMoa011489
Brenner, 2001, Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy, N Engl J Med, 345, 861, 10.1056/NEJMoa011161
Lewis, 2001, Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes, N Engl J Med, 345, 851, 10.1056/NEJMoa011303
Mann, 2008, Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial, Lancet, 372, 547, 10.1016/S0140-6736(08)61236-2
Fried, 2013, Combined angiotensin inhibition for the treatment of diabetic nephropathy, N Engl J Med, 369, 1892, 10.1056/NEJMoa1303154
Palevsky, 2016, Incidence, severity, and outcomes of AKI associated with dual renin-angiotensin system blockade, Clin J Am Soc Nephrol, 11, 1944, 10.2215/CJN.03470316
Parving, 2008, Aliskiren combined with losartan in type 2 diabetes and nephropathy, N Engl J Med, 358, 2433, 10.1056/NEJMoa0708379
Heerspink, 2016, Renal outcomes with aliskiren in patients with type 2 diabetes: A prespecified secondary analysis of the ALTITUDE randomised controlled trial, Lancet Diabetes Endocrinol, 4, 309, 10.1016/S2213-8587(15)00469-6
1998, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33), Lancet, 352, 837, 10.1016/S0140-6736(98)07019-6
Duckworth, 2009, Glucose control and vascular complications in veterans with type 2 diabetes, N Engl J Med, 360, 129, 10.1056/NEJMoa0808431
Perkovic, 2013, Intensive glucose control improves kidney outcomes in patients with type 2 diabetes, Kidney Int, 83, 517, 10.1038/ki.2012.401
Ismail-Beigi, 2010, Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: An analysis of the ACCORD randomised trial, Lancet, 376, 419, 10.1016/S0140-6736(10)60576-4
Cherney, 2014, Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus, Circulation, 129, 587, 10.1161/CIRCULATIONAHA.113.005081
Fioretto, 2016, Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment, Diabetologia, 59, 2036, 10.1007/s00125-016-4017-1
Wanner, 2016, Empagliflozin and progression of kidney disease in type 2 diabetes, N Engl J Med, 375, 323, 10.1056/NEJMoa1515920
Groop, 2013, Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction, Diabetes Care, 36, 3460, 10.2337/dc13-0323
Cornel, 2016, Effect of sitagliptin on kidney function and respective cardiovascular outcomes in type 2 diabetes: Outcomes from TECOS, Diabetes Care, 39, 2304, 10.2337/dc16-1415
2014, Effect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: A secondary analysis of the Look AHEAD randomised clinical trial, Lancet Diabetes Endocrinol, 2, 801, 10.1016/S2213-8587(14)70156-1
Friedman, 2016, Is bariatric surgery an effective treatment for type II diabetic kidney disease?, Clin J Am Soc Nephrol, 11, 528, 10.2215/CJN.07670715
Chang, 2016, Bariatric surgery is associated with improvement in kidney outcomes, Kidney Int, 90, 164, 10.1016/j.kint.2016.02.039
Sasser, 2007, Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism, J Am Soc Nephrol, 18, 143, 10.1681/ASN.2006030208
de Zeeuw, 2014, The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy, J Am Soc Nephrol, 25, 1083, 10.1681/ASN.2013080830
Schievink, 2016, Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers, Eur J Prev Cardiol, 23, 758, 10.1177/2047487315598709